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Abstract
Purpose Recently, multiple clinical trials have demonstrated improved outcomes in patients with metastatic colorectal cancer.
This study investigated if the improved survival is race dependent.
Patients and Methods Overall and cancer-specific survival of 77,490White and Black patients with metastatic colorectal cancer
from the 1988–2008 Surveillance Epidemiology and End Results registry were compared using unadjusted and multivariable
adjusted Cox proportional hazard regression as well as competing risk analyses.
Results Median age was 69 years, 47.4 % were female and 86.0 % White. Median survival was 11 months overall, with an
overall increase from 8 to 14months between 1988 and 2008. Overall survival increased from 8 to 14months forWhite, and from
6 to 13 months for Black patients. After multivariable adjustment, the following parameters were associated with better survival:
White, female, younger, better educated and married patients, patients with higher income and living in urban areas, patients with
rectosigmoid junction and rectal cancer, undergoing cancer-directed surgery, having well/moderately differentiated, and N0
tumors (p<0.05 for all covariates). Discrepancies in overall survival based on race did not change significantly over time;
however, there was a significant decrease of cancer-specific survival discrepancies over time between White and Black patients
with a hazard ratio of 0.995 (95 % confidence interval 0.991–1.000) per year (p=0.03).
Conclusion A clinically relevant overall survival increase was found from 1988 to 2008 in this population-based analysis for
both White and Black patients with metastatic colorectal cancer. Although both White and Black patients benefitted from this
improvement, a slight discrepancy between the two groups remained.
Keywords Metastatic colorectal cancer . Colon cancer .
Rectal cancer . Race . Disparity . Ethnicity . Survival
Introduction
Approximately 25 % of colorectal cancer (CRC) patients
present with metastatic disease while another 25 % develop
metastases during their disease course. Considering that colo-
rectal cancer is the third most common malignancy among
women and men, metastatic colorectal cancer represents a
tremendous public health problem.1 Over 140,000 new colo-
rectal cancer diagnoses and over 50,000 colorectal cancer
deaths are estimated to occur in 2013 in the USA.1 Fortunate-
ly, many randomized controlled trials over the past decade
have demonstrated improved outcomes in patients with met-
astatic colorectal cancer.2–4 A recent population-based report
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demonstrated a significant improvement in survival mainly in
young patients in the USAwith metastatic colorectal cancer,5
indicating that improved outcomes are indeed observed in
broader practice outside of the clinical trial setting.
However, racial disparities for CRC are known to exist.
Although the CRC-related mortality for Blacks has decreased
over the last 20 years, the overall magnitude of this decrease
lags behind that observed in White patients, particularly for
those presenting with metastatic disease.6 Speculation exists
that improved CRC outcomes demonstrated in clinical trials
have not been fully realized in the Black population due to
underutilization of newer CRC chemotherapy regimens, po-
tentially related to a lower frequency of obtaining care from
high volume, multidisciplinary centers.7–13 Not surprisingly,
health care-related disparities affecting minorities such as
those seen for CRC have been considered a top priority by
the US government.14 Whether any progress has been made
on a national level in improving these disparities, however,
remains unclear. In patients with metastatic colorectal cancer,
a paucity of data exists to determine whether racial differences
in overall and cancer-specific survival has equalized over time
with advances in managing this disease as well as heightened
awareness of disparities in care and outcomes. Our objective
was therefore to perform a population-based analysis, span-
ning more than two decades exploring racial survival dispar-
ities in patients with metastatic colorectal cancer.
Methods
Data on colorectal cancer patients were extracted from 1988 to
2008 from the US population-based Surveillance, Epidemiol-
ogy, and End Results (SEER) registry.15 SEER is the largest
US validated cancer registry and is sponsored by the National
Cancer Institute. This registry captures a vast amount of data
on approximately 28 % of cancer cases in the USA, including
patient characteristics, treatment (surgery and radiotherapy),
and survival information. Trained personnel systematically
collect information including patient characteristics, data on
tumor stage, tumor grading, overall survival (OS), cancer-
specific survival (CSS), and information regarding tumor-
directed surgery (e.g., removal of the primary tumor). How-
ever, data on comorbidities and chemotherapy cannot be
ascertained based on the SEER data.
SEER*Stat 7.0.5 was used to extract patients with meta-
static colorectal adenocarcinoma. The “SEER Site Recode”
variable was used to preliminary identify patients with a tumor
of the “colon,” the “rectosigmoid junction,” and the “rectum”;
further, the “Histologic Type ICD-O-3” (International Classi-
fication of Diseases for Oncology, third edition) variable was
used to limit the colorectal tumors to adenocarcinoma.16
Patients diagnosed with metastatic colorectal adenocarci-
noma from January 1, 1988 through December 31, 2008 aged
18 years and older were included. Patients diagnosed after
2008 were excluded to ensure sufficient follow-up time to
adequately evaluate survival outcomes. To explore racial dis-
parities among White and Black patients, the dataset was
limited to those two patient groups. Patients with metastatic
disease were identified through the variable “Extent of Dis-
ease” with the code 85 (metastatic disease) for years 1988–
2003 and the variable “Derived AJCCM 6th edition 2004” for
years 2004–2008 with M1 disease. Patients in whom the
tumor was diagnosed at autopsy or if it was first cited on the
death certificate were excluded from the study. The primary
outcome of interest was overall survival measured in months.
Secondary outcome was cancer-specific survival. Patients
who were still alive at the last reported date were right-
censored in the survival analysis. The primary predictor in
the analysis was year of diagnosis. To assess additional patient
specific predictors of overall and cancer-specific survival, the
following patient characteristics were extracted: age, gender,
marital status (married, other/unknown), tumor location (co-
lon, rectosigmoid junction, rectal), stage of nodal disease (N0,
N+, NX), tumor grade (well/moderately differentiated,
poor/undifferentiated, unknown), cancer-directed surgery, lo-
cation (rural, urban ≤250,000, urban ≥250,000 habitants),
percentage of education below high school (per ZIP code,
grouped in tertiles), and median family income per ZIP code
(grouped in tertiles). As information on T-stage was not avail-
able before 2004, we did not include this information in our
analysis.
Statistical Analysis and Outcomes
Demographical data and tumor characteristics are presented as
mean (standard deviation, SD) and median (interquartile
range, IQR) for continuous and counts (percentage) for cate-
gorical variables. Overall survival was first analyzed using the
Kaplan–Meier approach with survival curves compared using
the log-rank test. Kaplan–Meier curves for 5-year overall and
cancer-specific survival were drawn after right censoring of
patients who survived longer than 5 years. Second, unadjusted
andmultivariable adjusted Cox proportional hazard regression
analyses were performed to assess cumulative risk of death
among White and Black patients. The following covariates
were incorporated into the survival model: age (continuous
variable), gender, marital status, tumor location, N-stage, tu-
mor grade, cancer directed surgery, rural/urban location, edu-
cation below high school, and median family income. To
evaluate the trend in survival over time, we included year as
a predictor variable in unadjusted and adjusted Cox propor-
tional hazard models and quantified the related hazard ratio
from 1988 to 2008. To identify whether or not discrepancies in
racial survival changed over time, an interaction term between
race and year of cancer diagnosis was added to the model. It
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was a priori decided to keep only significant interaction terms
in the final model. All estimates are presented as hazard ratios
(HR) and related 95 % confidence intervals (CI). Similar
analyses were repeated for CSS; however, hazard ratios were
calculated according to competing-risk regression models de-
scribed by Fine and Gray accounting for the fact that cancer-
specific death prevents the occurrence of non-cancer-specific
death.17
To further elucidate potential racial disparities irrespective
of income, education, or urban/rural location, we performed
subgroup analyses for the following populations: (1) the tertile
with the lowest median family income; (2) the tertile with the
lowest education (based on the rate of high school comple-
tion); and (3) patients living in urban areas with >250,000
inhabitants. We additionally performed subgroup analyses for
patients aged 65 years or younger.
The p values for all analyses were calculated two-sided
while the significance level alpha was set at 0.05. All analyses
were performed using STATA 11.2/SE (Stata Corporation,
College Station, TX), with visual graphics compiled using
Microsoft Excel (Microsoft Corporation, Redmond, WA) or
JMP Pro Version 9.0.0 (SAS Institute Inc., Cary, NC).
Results
In total, 77,490 of 539,274 (14.4 %) colorectal cancer patients
in SEER met the inclusion criteria with histologically proven
metastatic colorectal adenocarcinoma (Fig. 1). Themajority of
the patients were White (n=66,668, 86.0 %) (Table 1). Medi-
an age was 69 years (IQR 58–78), 58.4 % of all patients were
older than 65 years of age, and 47.4 % (n=36,723) were
female. The localization of the primary tumor was in the
colon, at the rectosigmoid junction, and in the rectum in
75.4, 9.2, and 15.4 % of all patients, respectively. Overall,
66.0 % of patients underwent cancer-directed surgery (i.e.,
removal of the primary cancer). More Black patients (75.1 %)
lived in urban areas with a population >250,000 than White
patients (59.8 %). Demographically, Black patients resided in
an area with a higher percentage of people with education
below high school level compared toWhite patients, while the
median family income per ZIP code was higher for White
($49,818) than for Black patients ($47,689). Black patients
(mean=64.2 years, SD 13.4) were younger than White pa-
tients (67.9 years, SD 13.4) and less often married (39.6 vs.
55.7 %).
Overall Survival
For all patients in the study population combined, median OS
was 11 months (CI, 11–11), which increased from 8 months
(CI, 7–9) in 1988 to 14 months (CI, 13–15) in 2008 (Fig. 2).
Median CSS was 13 months (CI, 13–13) with an increase
from 10 months (CI, 9–10) in 1988 to 18 months (CI, 16–18)
in 2008. Median OS for White patients was 11 months (CI,
11–11) and 10 months (CI, 10–10) for Black patients. In
White patients, median OS increased from 8 months (CI, 8–
9) in 1988 to 14 months (CI, 14–15) in 2008 compared to
6 months (CI, 5–9) in 1988 and 13 months (CI, 11–14) in
2008 for Black patients (Fig. 3). Survival curves significantly
differed (p<0.001) between White and Black patients for OS
(Fig. 4).
Fig. 1 Flow chart of patient cohort definition
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Table 1 Patient demographics
All values are given as count and










Male 40,767 (52.6) 35,387 (53.1) 5,380 (49.7) <0.001
Female 36,723 (47.4) 31,281 (46.9) 5,442 (50.3)
Age
Mean SD 67,4 (13.5) 67.9 (13.4) 64.2 (13.4) <0.001
Median IQR 69 (58-78) 69 (59-78) 65 (55-74)
≤65 years 32,239 (41.6) 26,549 (39.8) 5,690 (52.6) <0.001
>65 years 45,251 (58.4) 40,119 (60.2) 5,132 (4.4)
Marital status
Married 41,388 (53.4) 37,099 (55.7) 4,289 (39.6) <0.001
Other/unknown 36,102 (46.6) 29,569 (44.3) 6,533 (60.4)
Tumor location
Colon 58,430 (75.4) 49,699 (74.5) 8,731 (80.7) <0.001
Rectosigmoid junction 7,091 (9.2) 6,265 (9.4) 826 (7.6)
Rectum 11,969 (15.4) 10,704 (16.1) 1,265 (11.7)
N-stage
N0 16,474 (21.3) 13,864 (20.8) 2,610 (24.1) <0.001
N+ 43.182 (55.7) 37,519 (56.3) 5,663 (52.3)
NX 17,834 (23.0) 15,285 (22.9) 2,549 (23.6)
Tumor grade
Well/moderately differentiated 43,542 (56.2) 37,030 (55.5) 6,512 (60.2) <0.001
Poor/undifferentiated 20,639 (26.6) 18,398 (27.6) 2,241 (20.7)
Unknown 13,309 (17.2) 11,240 (16.9) 2,069 (19.1)
Cancer-directed surgery
No 24,206 (31.2) 20,406 (30.6) 3,800 (35.1) <0.001
Yes 51,142 (66.0) 44,441 (66.7) 6,701 (61.9)
Unknown 2,142 (2.8) 1,821 (2.7) 321 (3.0)
Rural/urban
Rural 1,315 (1.7) 1,238 (1.9) 77 (0.7) <0.001
Urban ≤250,000 28,166 (36.4) 25,544 (38.3) 2,622 (24.2)
Urban >250,000 48,006 (61.9) 39,883 (59.8) 8,123 (75.1)
Unknown 3 (0) 3 (0) 0
Education below high school (%)
(mean, SD)
21.0 (7.3) 20.6 (7.3) 23.1 (6.8) <0.001
Group 1 (3.67–16.75) 25,579 (33.0) 23,163 (34.7) 2,416 (22.3) <0.001
Group 2 (16.77–22.96) 24,213 (31.3) 21.305 (32.0) 2,908 (26.9)
Group 3 (23.02–57.23) 27,695 (35,7) 22,197 (33.3) 5,498 (50.8)
Unknown 3 (0) 3 (0) 0
Median family income per ZIP
code (mean, SD)
49,521 (13,352) 49,818 (13,569) 47,689 (11,758) <0.001
Group 1 ($15,510–$44,040) 25,602 (33.0) 21,569 (32.4) 4,033 (37,3) <0.001
Group 2 ($44,050–$53,370) 25,933 (33.5) 22,130 (33.2) 3,803 (35.1)
Group 3 ($53,430–$91,050) 25,952 (33.5) 22,966 (34.4) 2,986 (27.6)
Unknown 3 (0) 3 (0) 0
Cause of death
Colorectal cancer 59,971 (77.4) 51.654 (77.5) 8,317 (76.9) <0.001
Other 10,400 (13.4) 8,815 (13.2) 1,585 (14.6)
Alive 7,119 (9.2) 6,199 (9.3) 920 (8.5)
Year
1988–1995 17,452 (22.5) 15,431 (23.2) 2,021 (18.7) <0.001
1996–2002 26,486 (34.2) 22,773 (34.2) 3,713 (34.3)
2003–2008 33,552 (43.3) 28,464 (42.7) 5,088 (47.0)
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In unadjusted Cox proportional hazard regression analyses
for OS, cumulative risk of all-cause mortality was higher for
Blacks compared to Whites (HR, 1.08; CI, 1.06–1.11;
p<0.001) (Table 2). For the combined study population
(White and Black), OS significantly improved per 1-year
increment (HR, 0.979; CI, 0.977–0.980; p<0.001). However,
the interaction term between race and year was not significant,
indicating the survival discrepancy between Whites and
Blacks did not change over time.
For all patients, improvedOS per 1-year increment retained
statistical significance upon multivariable adjusted analysis
(adjusted HR [aHR], 0.976; CI, 0.975–0.978; p<0.001). Pro-
portional hazard for all-cause mortality persisted to be higher
for Blacks compared to Whites (aHR, 1.13; CI, 1.11–1.16;
p<0.001). Similar to the unadjusted analysis, the discrepancy
in survival between Whites and Blacks did not change over
time as indicated by lack of significance for the interaction
term (aHR, 0.998; CI, 0.994–1.002; p=0.26). Focusing the
analysis to the most recent years of the study (2006 to 2008),
the adjusted HR for race was 1.12 (CI, 1.06–1.17; p<0.001),
again demonstrating higher mortality risk for Blacks com-
pared to Whites.
In multivariable adjusted analyses, the risk of dying (OS)
was lower compared to their counterparts for the following
patient groups: females, married and younger patients, tumor
locations in the rectosigmoid junction or in the rectum,
well/moderately differentiated tumors, patients with cancer-
directed surgery, patients living in urban regions and having a
higher education level, and a median family income of over
$53,430.
Cancer-Specific Survival
Results for CSS based on multivariable adjusted competing
risk analyses showed worse survival for Blacks compared to
Whites for year 1988 (aHR, 1.19; CI, 1.12–1.26; p<0.001)
and improved survival per 1-year increment over time (aHR,
0.959; CI, 0.957–0.961; p<0.001). Per 1-year increment,
there was a significant reduction of the difference in CSS
between Whites and Blacks (aHR for race/year interaction
term, 0.995; CI, 0.991–1.000; p=0.03) (Table 3). However,
limiting the analyses to patients from 2006 to 2008, the
adjusted HR (aHR, 1.10; CI, 1.04–1.17; p=0.001) continued
to demonstrate higher cancer-specific risk of death for Blacks
compared to Whites. Most of the other characteristics showed
similar results; however, no difference was found for gender
and median family income per ZIP code.
Subgroup Analyses
Multivariable adjusted subgroup analyses were performed for
four subgroups. For patients within the lowest income tertile,
results for OS and CSS showed that Blacks had worse survival
than Whites (aHR, 1.12; CI, 1.08–1.16, p<0.001; aHR, 1.11;
CI, 1.06–1.16, p<0.001, respectively), improved OS and CSS
per 1-year increment over time for the whole study population
(White and Black) (aHR, 0.978; CI, 0.976–0.981, p<0.001;
aHR, 0.963; CI, 0.960–0.967, p<0.001, respectively), while
there was no significant change in the discrepancy between
Blacks and Whites over time in OS and CSS (aHR interaction
term race×year, 0.995; CI, 0.989–1.001, p=0.12; aHR, 0.994;
CI, 0.987–1.001, p=0.09, respectively). For patients within
the highest tertile for education level below high school pro-
vided the following results: Blacks had worse OS and CSS
compared to Whites (aHR, 1.15; CI, 1.11–1.18, p<0.001;
aHR, 1.14; CI, 1.10–1.18, p<0.001, respectively), while OS
and CSS improved significantly per 1-year increment (aHR,
0.975; CI, 0.972–0.978, p<0.001; aHR, 0.955; CI, 0.952–
0.958, p<0.001, respectively). There was no significant
change in the survival discrepancy for OS and CSS between
Fig. 2 Trend ofmedian overall and cancer-specific survival from 1988 to
2008. OS overall survival, CSS cancer-specific survival, x-axis time
period (year), y-axis median survival in months, error bars 95 % confi-
dence interval
Fig. 3 Trend analysis of median overall (OS) and cancer-specific surviv-
al (CSS) from 1988 to 2008 for White and Black patients with metastatic
colorectal cancer patients. x-axis time period (year), y-axis median sur-
vival in months. OS overall survival, CSS cancer-specific survival
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Whites and Blacks over this time period (aHR interaction term
race×year, 0.998; CI, 0.992–1.004, p=0.46; aHR, 0.997; CI,
0.991–1.004, p=0.41, respectively). Among patients residing
in urban areas with more than 250,000 inhabitants, Blacks
have worse OS and CSS compared to Whites (aHR, 1.14; CI,
1.11–1.17, p<0.001; aHR, 1.14; CI, 1.11–1.17, p<0.001,
respectively) while OS and CSS significantly improved over
time per 1-year increment (aHR, 0.975; CI, 0.973–0.978,
p<0.001; aHR, 0.957; CI, 0.955–0.959, p<0.001). No chang-
es were found for the discrepancy in OS and CSS between
Whites and Blacks (aHR interaction term race×year, 1.000;
CI, 0.996–1.005, p=0.93; aHR, 0.998; CI, 0.993–1.003, p=
0.43, respectively). Among patients aged 65 years and youn-
ger, the adjusted HR of the interaction term between race and
year was not significant for OS (aHR, 1.000; CI, 0.994–1.005,
p=0.912) and for CSS (aHR, 0.999; CI, 0.993–1.005, p=
0.665).
Discussion
The present analysis provides compelling evidence that over-
all and cancer-specific survival have significantly improved
over the past two decades for both Black and White patients;
however, a significant racial survival discrepancy persists.
While improvement in this discrepancy over time was ob-
served for cancer-specific survival, the results were less en-
couraging for overall survival. By subgroup analysis, these
findings were confirmed among poor patients, poorly educat-
ed patients, and among patients living in urban areas with
>250,000 inhabitants.
The improvements in outcomes for patients with metastatic
colorectal cancer are likely due to a variety of factors. First,
surgical treatment for metastatic colorectal cancer has changed
over the past few decades. Indeed, more aggressive strategies
are performed for liver metastases,18 including portal vein
embolization to increase the liver remnant prior to resection,
two- and three-step procedures to clear the liver from
metastases,19 alternative methods such as radiofrequency ab-
lation to destroy metastases that cannot be resected,20 as well
as more aggressive surgical resection of lung metastases.21
Second, new, potentially beneficial strategies in the treatment
of metastatic colorectal cancer have been developed in recent
years.While a decade ago it was standard to resect the primary
tumor first, the so-called liver-first reversed management is
now often successfully used.22 Third, major advances have
been made in systemic treatment. Indeed, 10 years ago, only
two chemotherapeutic drugs (5-fluoropyrimidine and
irinotecan) were available for the treatment of metastatic co-
lorectal cancer, while the number of agents in the armamen-
tarium has significantly increased over the past decade. In
addition to more chemotherapeutic drugs such as oxaliplatin,2
there are also antibodies that now play an important role in the
treatment of metastatic colorectal cancer. Both anti-VEGF
antibodies4 as well as anti-EGFR-antibodies3,23 have shown
to improve outcomes in patients with metastatic colorectal
cancer. Moreover, new small molecules such as oral
multikinase inhibitors (e.g., Regorafenib)24 and so-called
VEGF-trap fusion proteins (e.g., Aflibercept)25 are success-
fully being used. Finally, new concepts have developed such
as continuing certain agents beyond progression. This has
been demonstrated in a recently published phase III trial, in
which bevacizumab was continued even if patients progressed
during first-line treatment.26 However, for the vast majority of
metastatic colorectal cancer patients treated from 1998 to
2008 in the present analysis, many of these newer agents
(e.g., anti-VEGF or anti-EGFR antibodies, oral multikinase
inhibitors, VEGF trap) were not yet available. Therefore, it
Fig. 4 Five-year survival curves
for overall and cancer-specific
survival stratified by race (White
vs. Black) for years 1988 to 2008
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remains to be seen in future analyses whether the rapid in-
crease in drugs in the armamentarium of metastatic colorectal
cancer patients will further improve outcomes on a
population-based level.
While it is encouraging that the discussed improvements
have significantly impacted overall and cancer-specific sur-
vival of both White and Black patients, the survival discrep-
ancy between those two groups only decreased for cancer
Table 2 Unadjusted and multi-
variable adjusted analyses of
overall survival
Ref. reference group, NA not ap-
plicable, interaction term race X
year not included in multivariable
adjusted analysis
Unadjusted hazard
ratio (95 % CI)
p value Adjusted hazard




Black 1.08 (1.06–1.11) <0.001 1.13 (1.11–1.16) <0.001
Year (continuous) 0.979 (0.977–0.980) <0.001 0.976 (0.975–0.978) <0.001
Race×year interaction 1.000 (0.996–1.004) 0.85 0.998 (0.994–1.002) 0.26
Age
Continuous 1.021 (1.020–1.022) <0.001 1.019 (1.019–1.020) <0.001
≤65 years Ref.
>65 years 1.55 (1.52–1.57) <0.001 NA
Gender
Male Ref. Ref.
Female 1.03 (1.02–1.05) <0.001 0.97 (0.95–0.98) <0.001
Marital status
Married 0.80 (0.79–0.81) <0.001 0.86 (0.85–0.88)
Unmarried Ref. Ref. <0.001
Tumor location
Colon Ref. Ref. <0.001
Rectosigmoid junction 0.83 (0.81–0.85) <0.001 0.84 (0.82–0.87) <0.001
Rectal 0.87 (0.86–0.89) 0.75 (0.74–0.77) <0.001
N-stage
N0 Ref. Ref.
N+ 1.14 (1.12–1.16) <0.001 1.36 (1.33–1.39) <0.001
NX 2.04 (1.99–2.08) <0.001 1.29 (1.26–1.33) <0.001
Tumor grade
Well/moderately differentiated Ref. Ref.
Poor/undifferentiated 1.40 (1.37–1.42) <0.001 1.42 (1.40–1.45) <0.001
Unknown 1.68 (1.65–1.72) <0.001 1.14 (1.11–1.17) <0.001
Cancer-directed surgery performed
No Ref. Ref.
Yes 0.49 (0.48–0.50) <0.001 0.43 (0.42–0.44) <0.001
Other/unknown 0.56 (0.54–0.59) <0.001 0.57 (0.55–0.60) <0.001
Rural/urban
Rural Ref. Ref.
Urban ≤250,000 0.92 (0.87–0.98) 0.008 0.94 (0.89–1.00) 0.04
Urban >250,000 0.92 (0.87–0.98) 0.008 0.93 (0.87–0.99) 0.02
Education below high school (%)
Group 1 (3.67–16.75) Ref. Ref.
Group 2 (16.77–22.96) 1.08 (1.06–1.10) <0.001 1.03 (1.01–1.05) 0.004
Group 3 (23.02–57.23) 1.09 (1.07–1.11) <0.001 1.05 (1.02–1.07) <0.001
Median family income per ZIP code
Group 1 ($15,510–$44,040) Ref. Ref.
Group 2 ($44,050–$53,370) 0.93 (0.92–0.95) <0.001 0.99 (0.97–1.01) 0.28
Group 3 ($53,430–$91,050) 0.84 (0.83–0.86) <0.001 0.94 (0.92–0.97) <0.001
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specific, but not for overall survival, over the last two decades.
The reason for such persistent racial differences is not well
understood. One factor that might contribute to worse overall
and cancer-specific survival in the Black population with
metastatic colorectal cancer is that this population commonly
presents with more advanced disease at the time of cancer
detection.7 Among all colorectal cancer patients recorded in
SEER from 2000 to 2010, 18.3 % of Whites and 22.9 % of
Table 3 Unadjusted and multi-
variable adjusted analyses of can-
cer-specific survival (competing
risk analyses)
Ref. reference group, NA not ap-
plicable, # for year 1988
Unadjusted hazard
ratio (95 % CI)
p value Adjusted hazard




Black 1.05 (1.03–1.08) <0.001 1.19 (1.12–1.26)# <0.001
Year (continuous) 0.963 (0.962–0.964) <0.001 0.959 (0.957–0.961) <0.001
Race×year interaction 0.998 (0.993–1.002) 0.25 0.995 (0.991–1.000) 0.03
Age
Continuous 1.018 (1.017–1.019) <0.001 1.016 (1.015–1.017) <0.001
≤65 years Ref. NA
>65 years 1.47 (1.45–1.50) <0.001
Gender
Male Ref. Ref.
Female 1.05 (1.03–1.07) <0.001 0.99 (0.97–1.01) 0.27
Marital status
Married 0.83 (0.82–0.85) <0.001 0.88 (0.87–0.90)
Unmarried Ref. Ref. <0.001
Tumor location
Colon Ref. Ref.
Rectosigmoid junction 0.84 (0.82–0.87) <0.001 0.85 (0.82–0.87) <0.001
Rectal 0.87 (0.85–0.89) <0.001 0.76 (0.75–0.78) <0.001
N-stage
N0 Ref. Ref. <0.001
N+ 1.21 (1.18–1.23) <0.001 1.41 (1.38–1.44) <0.001
NX 2.03 (1.98–2.09) <0.001 1.32 (1.28–1.36)
Tumor grade
Well/moderately differentiated Ref. Ref.
Poor/undifferentiated 1.41 (1.38–1.44) <0.001 1.43 (1.40–1.46) <0.001
Unknown 1.54 (1.50–1.57) <0.001 1.07 (1.04–1.10) <0.001
Cancer-directed surgery performed
No Ref. Ref.
Yes 0.54 (0.53–0.56) <0.001 0.45 (0.43–0.46) <0.001
Other/unknown 0.56 (0.53–0.60) <0.001 0.57 (0.54–0.60) <0.001
Rural/urban
Rural Ref. Ref.
Urban ≤250,000 0.94 (0.88–1.00) 0.04 0.95 (0.89–1.01) 0.09
Urban >250,000 0.93 (0.88–0.99) 0.03 0.91 (0.85–0.97) 0.004
Education below high school (%)
Group 1 (3.67–16.75) Ref. Ref.
Group 2 (16.77–22.96) 1.08 (1.06–1.10) <0.001 1.01 (0.99–1.03) 0.38
Group 3 (23.02–57.23) 1.06 (1.04–1.08) <0.001 1.04 (1.02–1.07) <0.001
Median family income per ZIP code
Group 1 ($15,510–$44,040) Ref. Ref.
Group 2 ($44,050–$53,370) 0.90 (0.88–0.92) <0.001 1.02 (1.00–1.05) 0.06
Group 3 ($53,430–$91,050) 0.80 (0.78–0.81) <0.001 1.00 (0.97–1.03) 0.92
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Blacks had distant disease at the time of diagnosis.15 Although
Black patients undergoing colorectal cancer screening have
significantly increased, there is still a lag compared to White
patients.27–29 Also, it has been demonstrated that Black pa-
tients are prone to underutilize newer, more effective treat-
ments in general and newer chemotherapy drugs for metastatic
colorectal cancer disease specifically.8–10 Beside differences
in access to care, Blacks have been shown to have a higher
degree of distrust in the health care system.30,31 It is also
suggested that patient-related factors existing prior to the
detection of metastatic colorectal cancer might be influential
for their outcome including comorbidities, diet, and physical
activity.32–34 Additionally, it has been shown that Black pa-
tients are less often treated in high volume and quality hospi-
tals, which has been associated with lower insurance
status.7,11–13 Our results support those findings to some extent
as patients with better education and higher incomes have
better OS compared to their counterparts. A report of Laiyemo
et al. highlights the importance of the differences in health
care utilization by race as its impact seems to exceed the
differences in tumor biology in explaining long-term out-
comes among colorectal cancer patients.35 Robbins et al. re-
cently reported that mortality rates overall for colorectal can-
cer significantly decreased from 1985 to 2008, while major
Black–White disparities persist especially for advanced stage
disease.6 Against the governmental aim of decreasing racial
disparity in the USA, they also reported that the differences in
mortality rates among Black and White patients with distant-
stage disease did indeed increase. Given the results of our
analysis, we were unable to support this finding while focus-
ing on survival time rather than survival rates. While SEER is
an excellent dataset to describe population-based trends in
outcomes of patients with metastatic colorectal cancer, it is
not possible to further assess detailed reasons for the differen-
tial outcomes between race.
As a result of the multivariable analysis, it is notable that
patients with metastatic colon cancer have a significantly
worse prognosis compared to patients with rectal cancer.
There are different explanations for this interesting phenome-
non: first, more treatment modalities are available for rectal
compared to colon cancer including radiation treatment. Sec-
ond, the introduction of total mesorectal excision (TME) has
resulted in a tremendous improvement of outcomes in rectal
cancer patients. Whether or not a complete mesocolic resec-
tion will lead to similar improvements in colon cancer patients
has still to be shown.36 Nonetheless, both surgery to the
primary tumor as well as radiation treatment are local treat-
ment modalities and it is questionable whether they impact
overall and cancer-specific survival in the setting of metastatic
disease.
Finally, overall and cancer-specific survival are highly
influenced by patient’s age. Golan et al. showed that the
prognosis of patients with metastatic colorectal cancer
significantly improved over the last years while this results
was mainly limited to patients age 70 and younger.5 This
finding is important as those are the patients mainly represent-
ed in randomized controlled trials as they more likely qualify
for aggressive surgical treatment and combination chemo-
immunotherapy.37 Based on those findings, we further tested
whether racial disparity between Whites and Blacks did im-
prove in the subgroup of younger patients (≤65 years). How-
ever, there was no change in survival difference between
Whites and Blacks over time in regard to overall and cancer-
specific survival in this subgroup of patients in our study.
We would like to acknowledge the inherent limitations of
this study. The main drawback of this analysis is the lack of
information on chemotherapeutic drugs or antibodies used,
data that cannot be ascertained in the SEER registry. Similarly,
information about comorbidities, performance status, and in-
formation on site of metastases are not available in the SEER
database. Second, for certain parameters (e.g., nodal status, T-
stage), there are a large number of missing values. While we
did include unknown nodal status as a separate group to the
multivariable analyses, we decided to avoid the inclusion of T-
stage. Despite these limitations, the present study has a variety
of strengths. First, the population-based nature of the registry
mirrors the real-world outcomes for White and Black patients
with metastatic colorectal cancer and is associated with a high
degree of generalizability. It is critically important to assess
disparity trends and to which extent advances in often highly
selected patients in randomized controlled trials have translat-
ed into the overall patient population. Secondly, our study
reports data on a 21-year time period. Finally, the large sample
size in this study results is associated with a high degree of
power.
In conclusion, the results and new treatment strategies
assessed by randomized controlled trials have translated to
significant improvements in OS and CSS over 21 years in a
large cohort of both White and Black patients with metastatic
colorectal cancer. However, the discrepancy between overall
survival for White and Black patients did not improve over
this time period while it slightly decreased for cancer-specific
survival. Further efforts are necessary to understand and cor-
rect these health care related disparities affecting minorities.
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